CGRP Mechanism Antagonists and Migraine Management

Current Neurology and Neuroscience Reports

Volumn 15, Issue 5, 2015, Pages 1-9

  Karsan, Nazia ^a   Goadsby, Peter J ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Calcitonin gene related peptide (CGRP); CGRP antagonists; Mechanisms of migraine; Migraine; Migraine management; Monoclonal antibodies

Indexed keywords

AA 32; AA 95; ALD 403; AMG 334; BI 44370; BMS 846372; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; ELETRIPTAN; LBR 101; LY 2951742; MK 3207; MONOCLONAL ANTIBODY; OLCEGEPANT; PLACEBO; RIMEGEPANT; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; UBROGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

BRAIN BLOOD FLOW; BRAIN STEM; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TARGETING; DRUG WITHDRAWAL; EPISODIC MIGRAINE; HUMAN; HYPERTRANSAMINASEMIA; LIVER DISEASE; LIVER TOXICITY; MENSTRUAL MIGRAINE; MIGRAINE; NERVOUS SYSTEM; NEUROPATHOLOGY; NONHUMAN; PARESTHESIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN LOCALIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; TRANSFORMED MIGRAINE; TRIGEMINAL NERVE; UNSPECIFIED SIDE EFFECT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MANAGEMENT; DRUG EFFECTS; METABOLISM; MIGRAINE DISORDERS; PATHOLOGY;

ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MANAGEMENT; HUMANS; MIGRAINE DISORDERS; NERVOUS SYSTEM; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 84925136291     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0547-z     Document Type: Review

References (79)

1. Amara SG, Jonas V, Rosenfeld MG, et al. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature. 1982;298(5871):240–4.
2. Mulderry PK, Ghatei MA, Spokes RA, et al. Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience. 1988;25(1):195–205.
3. Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6:573–82. An important review discussing the role of CGRP in migraine.
4. Moore EL, Salvatore CA. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine. Br J Pharmacol. 2012;166(1):66–78.
5. van Rossum D, Hanisch UK, Quirion R. Neuroanatomical localization, pharmacological characterization and functions of CGRP, related peptides and their receptors. Neurosci Biobehav Rev. 1997;21(5):649–78.
6. Unger JW, Lange W. Immunohistochemical mapping of neurophysins and calcitonin gene-related peptide in the human brainstem and cervical spinal cord. J Chem Neuroanat. 1991;4(4):299–309.
7. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23(2):193–6.
8. Zagami AS, Goadsby PJ, Edvinsson L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides. 1990;16(2):69–75.
9. Goadsby EE. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28:183–87.
10. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterising cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33:48–56.
11. Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–6.
12. Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179–86.
13. Sprenger T, Goadsby PJ. What has functional neuroimaging done for primary headache … and for the clinical neurologist? J Clin Neurosci: Off J Neurosurg Soc Australas. 2010;17(5):547–53.
14. Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128:932–39.
15. Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–41.
16. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurol. 2011;12:570–84. A review of the role of the brainstem in mediating the neuronal circuitry mechanism in migraine, current ideas regarding the pathophysiology of the condition and areas of the brain and circuitry that could be targeted with anti-migraine agents.
17. Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb blood flow Metab: Off J Int Soc Cereb Blood Flow Metab. 1987;7(6):720–8.
18. Arimura A. Pituitary adenylate cyclase activating polypeptide (PACAP): discovery and current status of research. Regul Pept. 1992;37(3):287–303.
19. Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–95.
20. Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide (PACAP) and Migraine. Ann Clin Transl Neurol. 2014. in press.
21. Lundberg JM, Franco-Cereceda A, Hua X, et al. Co-existence of substance P and calcitonin gene-related peptide-like immunoreactivities in sensory nerves in relation to cardiovascular and bronchoconstrictor effects of capsaicin. Eur J Pharmacol. 1985;108(3):315–9.
22. Uddman R, Edvinsson L, Ekman R, et al. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett. 1985;62(1):131–6.
23. Goadsby PJ. Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med. 2007;13(1):39–44.
24. Evans BN, Rosenblatt MI, Mnayer LO, et al. CGRP-RCP, a novel protein required for signal transduction at calcitonin gene-related peptide and adrenomedullin receptors. J Biol Chem. 2000;275(40):31438–43.
25. Maniyar FH, Sprenger T, Schankin C, Goadsby PJ. Photic hypersensitivity in the premonitory phase of migraine- a positron emission topography study. Eur J Neurol. 2014;21:1178–83.
26. Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3(6):369–78.
27. Lennerz JK, Ruhle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neurol. 2008;507(3):1277–99.
28. Liu Y, Broman J, Zhang M, Edvinsson L. Brainstem and thalamic projections from a craniovascular sensory nervous centre in the rostral cervical spinal dorsal horn of rats. Cephalalgia. 2009;29(9):935–48.
29. Smith D, Hill RG, Edvinsson L, Longmore J. An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia. 2002;22(6):424–31.
30. Strata P, Thach WT, Ottersen OP. New insights in cerebellar function. Introduction. Neuroscience. 2009;162(3):545–8.
31. Kawai Y, Takami K, Shiosaka S, et al. Topographic localization of calcitonin gene-related peptide in the rat brain: an immunohistochemical analysis. Neuroscience. 1985;15(3):747–63.
32. Brighina F, Palermo A, Panetta ML, et al. Reduced cerebellar inhibition in migraine with aura: a TMS study. Cerebellum (Lond, Engl). 2009;8(3):260–6.
33. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001;357(9261):1016–7.
34. Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010;169(2):683–96.
35. Edvinsson L. Calcitonin gene-related peptide (CGRP) and the pathophysiology of headache: therapeutic implications. CNS Drugs. 2001;15(10):745–53.
36. Lynch Jr JJ, Regan CP, Edvinsson L, et al. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J Cardiovasc Pharmacol. 2010;55(5):518–21.
37. Bigal ME, Walter S. Monoclonal antibodies for migraine: preventing calcitonin gene-related peptide activity. CNS Drugs. 2014;28(5):389–99.
38. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol. 2000;129(3):420–3.
39. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004;350(11):1104–10.
40. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem. 2002;277(16):14294–8.
41. Just S, Arndt K, Doods H. The role of CGRP and nicotinic receptors in centrally evoked facial blood flow changes. Neurosci Lett. 2005;381(1–2):120–4.
42. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005;25(2):139–47.
43. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet. 2010;376(9741):645–55.
44. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372(9656):2115–23.
45. Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014;83(11):958–66.
46. Ho TW, Ho AP, Chaitman BR, et al. Randomized, controlled study of telcagepant in patients with migraine and coronary artery disease. Headache. 2012;52(2):224–35.
47. Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009;73(12):970–7.
48. Han TH, Blanchard RL, Palcza J, et al. Single- and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J Clin Pharmacol. 2010;50(12):1367–76.
49. Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010;30(12):1443–57.
50. Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011;51(1):73–84.
51. Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011;31(6):712–22.
52. Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–84.
53. Luo G, Chen L, Conway CM, et al. Discovery of BMS-846372, a potent and orally active human CGRP receptor antagonist for the treatment of migraine. ACS Med Chem Lett. 2012;3(4):337–41.
54. Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo-controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–25.
55. Merck Sharp, Bohme Corp. A pharmacokinetic study of MK-1602 in the treatment of acute migraine (MK-1602-007) NCT01657370. https://clinicaltrials.gov/ct2/show/NCT01657370. Accessed 14 Mar 2015.
56. Merck Sharp, Bohme Corp. A dose-finding study of MK-1602 in the treatment of acute migraine (MK-1602-006) NCT01613248. https://clinicaltrials.gov/ct2/show/NCT01613248. Accessed 14 Mar 2015.
57. Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol. 2008;155(7):967–9.
58. Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347(2):478–86.
59. Baumann A. Early development of therapeutic biologics—pharmacokinetics. Curr Drug Metab. 2006;7(1):15–21.
60. Bigal ME, Walter S, Rapoport AM. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache. 2013;53(8):1230–44. An up to date current review on the anti-CGRP agents in migraine management, with a particular focus on the monoclonal antibodies.
61. Descotes J. Immunotoxicity of monoclonal antibodies. mAbs. 2009;1(2):104–11.
62. Feuerstein G, Willette R, Aiyar N. Clinical perspectives of calcitonin gene related peptide pharmacology. Can J Physiol Pharmacol. 1995;73(7):1070–4.
63. Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol. 2008;155(7):1093–103.
64. Alder biopharmaceuticals Inc. Safety tolerability and pharmacokinetics of ALD403 NCT01579383. https://clinicaltrials.gov/ct2/show/NCT01579383. Accessed 14 Mar 2015.
65. Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014;13(11):1100–7.
66. Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014;13(9):885–92.
67. Amgen. Ascending multiple-doses of AMG 334 in healthy subjects and in migraine patients NCT01723514. https://clinicaltrials.gov/ct2/show/NCT01723514. Accessed 14 Mar 2014.
68. Amgen. Ascending single doses of AMG 334 in healthy subjects and migraine patients NCT01688739. https://www.clinicaltrials.gov/ct2/show/NCT01688739. Accessed 14 Mar 2015.
69. Amgen. A phase 2 study to evaluate the efficacy and safety of AMG 334 in migraine prevention NCT01952574. https://clinicaltrials.gov/ct2/show/NCT01952574. Accessed 14 Mar 2015.
70. Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention NCT02174861. https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 14 Mar 2015.
71. Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program. Cephalalgia. 2013;34(7):483–92.
72. Teva Pharmaceutical Industries. A multicenter assessment of LBR-101 in high frequency episodic migraine NCT02025556. https://clinicaltrials.gov/ct2/show/NCT02025556. Accessed 14 Mar 2015.
73. Teva Pharmaceutical Industries. Assessment of LBR-101 In chronic migraine NCT02021773. https://clinicaltrials.gov/ct2/show/NCT02021773. Accessed 14 Mar 2015.
74. Walter S, Alibhoy A, Escandon R, Bigal ME. Evaluation of cardiovascular parameters in cynomolgus monkeys following IV administration of LBR-101, a monoclonal antibody against calcitonin gene-related peptide. mAbs. 2014;6(4):871–8.
75. Bigal ME, Walter S, Bronson M, et al. Cardiovascular and hemodynamic parameters in women following prolonged CGRP inhibition using LBR-101, a monoclonal antibody against CGRP. Cephalalgia 2014.
76. Goadsby PJ, Edvinsson L. Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies. Brain. 1994;117(Pt 3):427–34.
77. Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010;9(3):285–98.
78. Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25.
79. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.